A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges
Summary: People diagnosed with cancer and their formal and informal caregivers are increasingly faced with a deluge of complex information,
Safety and outcome of children, adolescents and young adults participating in phase I/II clinical oncology trials: a 9-year center experience
https://pubmed.ncbi.nlm.nih.gov/39318620/ Front Pediatr . 2024 Sep 4:12:1423484. doi: 10.3389/fped.2024.1423484. eCollection 2024.
Two decades of advances in clinical oncology — lessons learned and future directions
Two decades of advances in clinical oncology — lessons learned and future directions. Nat Rev Clin Oncol 21, 771–780 (2024). https://doi.org/10.1038/s41571-024-00945-4
Defining precancer: a grand challenge for the cancer community
Nat Rev Cancer 2024 Nov;24(11):792-809. doi: 10.1038/s41568-024-00744-0. Epub 2024 Oct 1. https://pubmed.ncbi.nlm.nih.gov/39354069/
The Epigenetic Hallmarks of Cancer
Abstract Cancer is a complex disease in which several molecular and cellular pathways converge to foster the tumoral phenotype. Notably,
The hallmarks of cancer immune evasion
Abstract According to the widely accepted "three Es" model, the host immune system eliminates malignant cell precursors and contains microscopic
Treatment of isolated pediatric optic nerve glioma: A nationwide retrospective cohort study and systematic literature review on visual and radiological outcome
Rosettes are little round groupings of cells found in tumors.
Assessment of cancer predisposition syndromes in children with leukemia and solid tumors: germline-genomic profiling and clinical features in a series of cases
Abstract Cancer predisposition syndromes (CPS) are a group of genetic disorders that increase the risk of various cancers. Identifying CPS
Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology Group
Abstract Background Response to induction chemotherapy has been shown to predict outcome in patients with high-risk neuroblastoma (HR-NB), with those
